Laryngeal Small Cell Carcinoma
Associated Genetic Biomarkers
NCI Definition: A rare carcinoma that arises from the larynx. It is characterized by the presence of small neuroendocrine cells. It metastasizes early and has an aggressive clinical course. 
There is 1 clinical trial for laryngeal small cell carcinoma, of which 1 is open and 0 are completed or closed. Of the trial that contains laryngeal small cell carcinoma as an inclusion criterion, 1 is phase 3 (1 open).
CDKN2A and HPV are the most frequent gene inclusion criteria for laryngeal small cell carcinoma clinical trials .
Cetuximab and palbociclib are the most common interventions in laryngeal small cell carcinoma clinical trials.
Significant Genes in Laryngeal Small Cell Carcinoma
CDKN2A is an inclusion eligibility criterion in 1 clinical trial for laryngeal small cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and laryngeal small cell carcinoma as inclusion criteria, 1 is phase 3 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.